

## Special Issue

# Advancing Vaccine Research: Contributions from Molecular, Cellular, and Omics Approaches

### Message from the Guest Editors

Vaccines have long been proven a highly efficient means to confer protection to various infectious diseases, and a rush for protective vaccines against SARS-CoV-2 is ongoing. The fast-developing field of omics sciences is delivering a deluge of nucleotide and protein sequence data from pathogens that, together with powerful bioinformatics tools and databases, are prompting astonishing advances in vaccine development. Advances in cell biology are unravelling nonconventional structures such as membrane vesicles as potential sources and vehicles of antigen presentation and delivery. This Special Issue aims to gather papers that use omics approaches such as genomics and proteomics, alternative biological structures such as extracellular vesicles, or innovative experimental methodologies to identify antigens for subunit vaccine investigation and development, as well as papers on bioinformatics tools, databases, and high-throughput techniques and instrumentation, in order to help in vaccine research and development. Papers in all formats accepted in the journal are welcome.

---

### Guest Editors

Prof. Dr. Jorge H. Leitão

Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisboa, Portugal

Prof. Dr. Manuel José Rodríguez-Ortega

Departamento de Bioquímica y Biología Molecular, Universidad de Córdoba Edificio Severo Ochoa Planta Baja, Campus de Rabanales, 14071 Córdoba, Spain

---

### Deadline for manuscript submissions

closed (15 February 2022)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/64892](https://mdpi.com/si/64892)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).